{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:05:19Z","timestamp":1793210719625,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>For patients with recurrent flares of gout, tophi, urate crystal arthropathy, and renal stones, urate-lowering therapies (ULTs, including allopurinol and febuxostat) are the first-line treatment. Due to the widespread use of these ULTs (especially in patients with impaired renal function), assessment of the associated renal risk is essential. Accordingly, we performed a disproportionality analysis of reported cases of acute renal failure (ARF) associated with allopurinol and febuxostat.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We carried out a case\/non-case study of the World Health Organization\u2019s VigiBase\u00ae pharmacovigilance database between January 1, 2008, and December 31, 2018. The frequency of reports of ARF as a standardized Medical Dictionary for Regulatory Activities query for allopurinol and febuxostat was compared with that of all other reports for the two drugs and quoted as the reporting odds ratio (ROR) [95% confidence interval (CI)]. The results\u2019 stability was assessed in a series of sensitivity analyses (notably after the exclusion of putative competing drugs).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 3509 \u201csuspected drug\u201d notifications for febuxostat and 18,730 for allopurinol, we identified respectively 317 and 1008 cases of ARF. Acute renal failure was reported significantly more frequently for febuxostat and allopurinol than for other drugs (ROR [95%CI] 5.67 [5.05\u20136.36] and 3.25 [3.05\u20133.47], respectively). For both drugs, the ROR was higher in women than in men, respectively 11.60 [9.74\u201313.82] vs. 3.14 [2.69\u20133.67] for febuxostat and 4.45 [4.04\u20134.91] vs. 2.29 [2.11\u20132.50] for allopurinol. The sensitivity analyses confirmed the disproportionality for these two ULTs.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Acute renal failure was reported respectively 5.7 and 3.3 times more frequently for febuxostat and for allopurinol than for other drugs. Due to the potential consequences of ARF, physicians should take account of this disproportionality signal when prescribing the ULTs febuxostat and allopurinol.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-019-2011-y","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T15:36:12Z","timestamp":1573227372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study"],"prefix":"10.1186","volume":"21","author":[{"given":"Amayelle","family":"Rey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Batteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne M.","family":"Laville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Marienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Masmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5384-9006","authenticated-orcid":false,"given":"Sophie","family":"Liabeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"issue":"11","key":"2011_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"C-F Kuo","year":"2015","unstructured":"Kuo C-F, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2011_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123.","journal-title":"BMC Med"},{"issue":"4","key":"2011_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"C-F Kuo","year":"2015","unstructured":"Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2011_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2011_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res"},{"key":"2011_CR6","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.12659\/MSM.899852","volume":"22","author":"C Chen","year":"2016","unstructured":"Chen C, L\u00fc J-M, Yao Q. Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview. Med Sci Monit. 2016;22:2501\u201312.","journal-title":"Med Sci Monit"},{"key":"2011_CR7","first-page":"35","volume-title":"Contributions to Nephrology","author":"F. Pea","year":"2004","unstructured":"Pea F. Pharmacology of drugs for hyperuricemia. In: Ronco C, Rodeghiero F, \u00e9diteurs. Contributions to nephrology [Internet]. Basel: KARGER; 2004. p. 35-46. [cit\u00e9 3 sept 2019]. Disponible sur: \nhttps:\/\/www.karger.com\/Article\/FullText\/82540\n\n."},{"issue":"12","key":"2011_CR8","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","volume":"74","author":"W-H Chung","year":"2015","unstructured":"Chung W-H, Chang W-C, Stocker SL, Juo C-G, Graham GG, Lee M-HH, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2011_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Am J Med. 1984;76(1):47\u201356.","journal-title":"Am J Med"},{"issue":"5","key":"2011_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40262-016-0466-4","volume":"56","author":"B Kamel","year":"2017","unstructured":"Kamel B, Graham GG, Williams KM, Pile KD, Day RO. Clinical pharmacokinetics and pharmacodynamics of febuxostat. Clin Pharmacokinet. 2017;56(5):459\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2011_CR11","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2011_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273\u201382.","journal-title":"J Rheumatol"},{"issue":"11","key":"2011_CR13","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher","year":"2008","unstructured":"Schumacher HR, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2011_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3810\/pgm.2013.01.2626","volume":"125","author":"A Whelton","year":"2013","unstructured":"Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125(1):106\u201314.","journal-title":"Postgrad Med"},{"issue":"8","key":"2011_CR15","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/art.39654","volume":"68","author":"KG Saag","year":"2016","unstructured":"Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment: febuxostat in patients with renal impairment. Arthritis Rheumatol. 2016;68(8):2035\u201343.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2011_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/bcp.13216","volume":"83","author":"M Pierson-Marchandise","year":"2017","unstructured":"Pierson-Marchandise M, Gras V, Moragny J, Micallef J, Gaboriau L, Picard S, et al. The drugs that mostly frequently induce acute kidney injury: a case \u2212 noncase study of a pharmacovigilance database: drug-induced acute kidney injury. Br J Clin Pharmacol. 2017;83(6):1341\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2011_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ccc.2015.06.005","volume":"31","author":"SL Kane-Gill","year":"2015","unstructured":"Kane-Gill SL, Goldstein SL. Drug-induced acute kidney injury. Crit Care Clin. 2015;31(4):675\u201384.","journal-title":"Crit Care Clin"},{"issue":"6","key":"2011_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/01.ccx.0000247448.94252.5a","volume":"12","author":"S Uchino","year":"2006","unstructured":"Uchino S. The epidemiology of acute renal failure in the world. Curr Opin Crit Care. 2006;12(6):538\u201343.","journal-title":"Curr Opin Crit Care"},{"key":"2011_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/691013","volume":"2012","author":"R Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba R, Kashiouris M, Plataki M, Kor DJ, Gajic O, Casey ET. Risk factors for development of acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies. Crit Care Res Pract. 2012;2012:1\u201315.","journal-title":"Crit Care Res Pract"},{"issue":"6","key":"2011_CR20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MCC.0000000000000453","volume":"23","author":"L Awdishu","year":"2017","unstructured":"Awdishu L. Drug-induced kidney disease in the ICU: mechanisms, susceptibility, diagnosis and management strategies. Curr Opin Crit Care. 2017;23(6):484\u201390.","journal-title":"Curr Opin Crit Care"},{"issue":"6","key":"2011_CR21","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798\u2013810.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2011_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf J. 2008;42(5):409\u201319.","journal-title":"Drug Inf J"},{"issue":"2","key":"2011_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"2","key":"2011_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"2011_CR25","unstructured":"vigibase-the-vital-importance-of-quality-2017.pdf [Internet]. [cit\u00e9 19 juin 2019]. Disponible sur: \nhttps:\/\/www.who-umc.org\/media\/163807\/vigibase-the-vital-importance-of-quality-2017.pdf\n\n."},{"issue":"4","key":"2011_CR26","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204.","journal-title":"Crit Care"},{"issue":"4","key":"2011_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1300\/J079v21n04_02","volume":"21","author":"JA Rosenthal","year":"1996","unstructured":"Rosenthal JA. Qualitative descriptors of strength of association and effect size. J Soc Serv Res. 1996;21(4):37\u201359.","journal-title":"J Soc Serv Res"},{"issue":"6","key":"2011_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","volume":"24","author":"NR Hartnell","year":"2004","unstructured":"Hartnell NR, Wilson JP. Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004;24(6):743\u20139.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2011_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/00002018-200124030-00006","volume":"24","author":"EJ Wallenstein","year":"2001","unstructured":"Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the weber effect revisited. Drug Saf. 2001;24(3):233\u20137.","journal-title":"Drug Saf"},{"issue":"6","key":"2011_CR30","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database: commentary. Br J Clin Pharmacol. 2011;72(6):905\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2011_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","volume":"73","author":"J-L Faillie","year":"2018","unstructured":"Faillie J-L. Les \u00e9tudes cas\u2013non cas : principe, m\u00e9thodes, biais et interpr\u00e9tations. Therapies. 2018;73(3):247\u201355.","journal-title":"Therapies"},{"issue":"11","key":"2011_CR32","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/pds.2022","volume":"19","author":"A Pariente","year":"2010","unstructured":"Pariente A, Didailler M, Avillach P, Miremont-Salam\u00e9 G, Fourrier-Reglat A, Haramburu F, et al. A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf. 2010;19(11):1166\u201371.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2011_CR33","doi-asserted-by":"publisher","unstructured":"Ghane Shahrbaf F. Drug-induced renal disorders. Drug-Induc Ren Disord. 2015;(3). [cit\u00e9 19 juin 2019]. Disponible sur: \nhttps:\/\/doi.org\/10.12861\/jrip.2015.12\n\n.","DOI":"10.12861\/jrip.2015.12"},{"issue":"1","key":"2011_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/fcp.12406","volume":"33","author":"F Montastruc","year":"2019","unstructured":"Montastruc F, Benevent J, Rousseau V, Durrieu G, Sommet A, Montastruc J-L. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase\u00ae. Fundam Clin Pharmacol. 2019;33(1):108\u201312.","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"2011_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1214243","volume":"371","author":"LS Chawla","year":"2014","unstructured":"Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58\u201366.","journal-title":"N Engl J Med"},{"issue":"8","key":"2011_CR36","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1681\/ASN.2015010006","volume":"26","author":"MA Venkatachalam","year":"2015","unstructured":"Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. 2015;26(8):1765\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2011_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.kint.2017.06.030","volume":"92","author":"L He","year":"2017","unstructured":"He L, Wei Q, Liu J, Yi M, Liu Y, Liu H, et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017;92(5):1071\u201383.","journal-title":"Kidney Int"},{"key":"#cr-split#-2011_CR38.1","doi-asserted-by":"crossref","unstructured":"Prasad Sah OS, Qing YX. Associations between hyperuricemia and chronic kidney disease: a review. Nephro-Urol Mon. 2015;7","DOI":"10.5812\/numonthly.7(3)2015.27233"},{"key":"#cr-split#-2011_CR38.2","unstructured":"(3) [cit\u00e9 19 juin 2019]. Disponible sur:  http:\/\/numonthly.com\/en\/articles\/17199.html  ."},{"issue":"12","key":"2011_CR39","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1111\/bcp.13738","volume":"84","author":"SM Laville","year":"2018","unstructured":"Laville SM, Metzger M, Stengel B, Jacquelinet C, Combe C, Fouque D, et al. Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort: adequacy of drug prescriptions in CKD patients. Br J Clin Pharmacol. 2018;84(12):2811\u201323.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2011_CR40","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/bcp.13798","volume":"85","author":"LK Stamp","year":"2019","unstructured":"Stamp LK, Wright DFB, Dalbeth N. Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate! Br J Clin Pharmacol. 2019;85(6):1378\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2011_CR41","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529\u201336.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2011_CR42","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1001\/jamainternmed.2018.4463","volume":"178","author":"AB Vargas-Santos","year":"2018","unstructured":"Vargas-Santos AB, Peloquin CE, Zhang Y, Neogi T. Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med. 2018;178(11):1526.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2011_CR43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.23876\/j.krcp.2017.36.3.274","volume":"36","author":"S Kim","year":"2017","unstructured":"Kim S, Kim H-J, Ahn H-S, Oh SW, Han KH, Um T-H, et al. Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: a systematic review and meta-analysis. Kidney Res Clin Pract. 2017;36(3):274\u201381.","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"2011_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/art.40685","volume":"71","author":"KG Saag","year":"2019","unstructured":"Saag KG, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, et al. Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo-controlled study. Arthritis Rheumatol. 2019;71(1):143\u201353.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2011_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13054-015-1049-8","volume":"19","author":"M Ikeda","year":"2015","unstructured":"Ikeda M, Swide T, Vayl A, Lahm T, Anderson S, Hutchens MP. Estrogen administered after cardiac arrest and cardiopulmonary resuscitation ameliorates acute kidney injury in a sex- and age-specific manner. Crit Care. 2015;19(1):332.","journal-title":"Crit Care"},{"issue":"3","key":"2011_CR46","doi-asserted-by":"publisher","first-page":"F740","DOI":"10.1152\/ajprenal.00049.2017","volume":"313","author":"R Boddu","year":"2017","unstructured":"Boddu R, Fan C, Rangarajan S, Sunil B, Bolisetty S, Curtis LM. Unique sex- and age-dependent effects in protective pathways in acute kidney injury. Am J Physiol-Ren Physiol. 2017;313(3):F740\u201355.","journal-title":"Am J Physiol-Ren Physiol"},{"issue":"5","key":"2011_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000088171","volume":"25","author":"Q Wei","year":"2005","unstructured":"Wei Q, Wang M-H, Dong Z. Differential gender differences in ischemic and nephrotoxic acute renal failure. Am J Nephrol. 2005;25(5):491\u20139.","journal-title":"Am J Nephrol"},{"issue":"3","key":"2011_CR48","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jaci.2010.11.046","volume":"127","author":"EJ Phillips","year":"2011","unstructured":"Phillips EJ, Chung W-H, Mockenhaupt M, Roujeau J-C, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011;127(3):S60\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2011_CR49","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40615-015-0101-3","volume":"2","author":"A Baehr","year":"2015","unstructured":"Baehr A, Pe\u00f1a JC, Hu DJ. Racial and ethnic disparities in adverse drug events: a systematic review of the literature. J Racial Ethn Health Disparities. 2015;2(4):527\u201336.","journal-title":"J Racial Ethn Health Disparities"},{"key":"2011_CR50","unstructured":"UMC | VigiBase [Internet]. [cit\u00e9 19 juin 2019]. Disponible sur: \nhttps:\/\/www.who-umc.org\/vigibase\/vigibase\/\n\n."},{"issue":"5","key":"2011_CR51","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"2","key":"2011_CR52","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","volume":"22","author":"A Bate","year":"2008","unstructured":"Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol. 2008;22(2):127\u201340.","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"2011_CR53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF03256733","volume":"22","author":"Y Chen","year":"2008","unstructured":"Chen Y, Guo JJ, Steinbuch M, Lin X, Buncher CR, Patel NC. Comparison of sensitivity and timing of early signal detection of four frequently used signal detection methods: an empirical study based on the US FDA adverse event reporting system database. Pharm Med. 2008;22(6):359\u201365.","journal-title":"Pharm Med"},{"issue":"6","key":"2011_CR54","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1053\/j.ajkd.2008.11.034","volume":"53","author":"SG Coca","year":"2009","unstructured":"Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53(6):961\u201373.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2011_CR55","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2174\/1573403X12666160606121458","volume":"12","author":"P Iyngkaran","year":"2016","unstructured":"Iyngkaran P, Liew D, McDonald P, C. Thomas M, Reid C, Chew D, et al. Phase 4 studies in heart failure - what is done and what is needed? Curr Cardiol Rev. 2016;12(3):216\u201330.","journal-title":"Curr Cardiol Rev"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-2011-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-2011-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-2011-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:48:43Z","timestamp":1604710123000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-2011-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2011"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-2011-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}